RxDoctor Payments Data
★ My doctorsLook up a doctor →

Dane Dickson, MD

Hematology & Oncology · Rexburg, IDNPI 1669497194

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (40.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Exact Sciences at 41.0% of the total. Reporting peaked in 2023 at $10,025 and has fallen 83.5% since, to $1,658 in 2025. Among hematology & oncology clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,155in general payments, 2019–2025

Across 517 payments — averaging $40.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$9K
  • Advanced Accelerator Applications$3K
  • Pfizer$820
  • Novartis$752
  • AstraZeneca$716
  • E.r. Squibb & Sons, L.L.C.$646
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$7,61036%
  • Speaking & faculty fees$3,00014%
  • Travel & lodging$1,2826%
  • Food & beverage$8,60241%
  • Education$6613%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences3$8,671
Advanced Accelerator Applications1$3,000
Pfizer65$820
Novartis27$752
AstraZeneca(2 entities)37$716
E.r. Squibb & Sons, L.L.C.47$646
Johnson & Johnson(2 entities)27$570
Astellas Pharma US Inc26$549
Merck26$460
Sanofi23$441
Daiichi Sankyo Inc.23$435
Amgen22$372
Eisai Inc.18$304
Genentech USA, Inc.16$275
Gilead(2 entities)10$260
Bristol Myers Squibb12$219
AbbVie11$213
Lilly USA, LLC11$187
Boehringer Ingelheim8$156
Coherus Oncology, Inc.2$151
Tersera Therapeutics LLC6$142
AVEO Pharmaceuticals, Inc.3$136
EMD Serono, Inc.8$133
Rigel Pharmaceuticals, Inc.5$100
GSK5$83
Bayer5$79
Deciphera Pharmaceuticals Inc.3$77
Incyte Corporation4$70
Takeda Pharmaceuticals U.S.A., Inc.3$61
Genmab U.S., Inc.3$58
Agios Pharmaceuticals, Inc.3$57
Seagen Inc.3$56
Regeneron Healthcare Solutions, Inc.3$52
Ipsen Biopharmaceuticals, Inc3$52
Pharmacyclics LLC, An Abbvie Company3$51
Geron Corporation2$47
Sobi, Inc3$44
Taiho Oncology, Inc.2$44
Sumitomo Pharma America, Inc.2$42
Servier Pharmaceuticals LLC2$37
Blueprint Medicines Corporation2$36
Springworks Therapeutics, Inc.2$35
Myovant Sciences Inc.2$34
Legend Biotech USA Inc.1$33
Adaptive Biotechnologies Corporation1$33
Puma Biotechnology, Inc.2$32
Dendreon Pharmaceuticals LLC1$28
Beigene USA, Inc.2$28
Medtronic1$24
Iovance Biotherapeutics, Inc.1$22
Syndax Pharmaceuticals, Inc.1$22
Secura Bio, Inc.3$21
Spectrum Pharmaceuticals Inc.1$20
Karyopharm Therapeutics Inc.1$20
Azurity Pharmaceuticals, Inc.1$19
Mirati Therapeutics, Inc.1$18
Jazz Pharmaceuticals Inc.1$16
Novocure Inc.1$15
Clovis Oncology, Inc.1$14
Alnylam Pharmaceuticals Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,155 in reported general payments places this provider in the 90th percentile of 34 hematology & oncology providers in Idaho.

See all hematology & oncology providers in Idaho →

Medicare billing

Part B allowed, 2024
$25,897
Medicare patients
137
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide15$185,376
XtandiEnzalutamide13$178,388
ErleadaApalutamide11$157,086
Tamoxifen Citrate57$1,531
Anastrozole58$893
Letrozole29$535
Potassium Chloride22$288
Raloxifene Hcl15$270
Levothyroxine Sodium29$223
Pantoprazole Sodium11$186
Omeprazole18$128
Alendronate Sodium23$54
Citalopram HbrCitalopram Hydrobromide11$44
Trazodone Hcl13$26

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$549$178,38813 claims
Johnson & JohnsonErleada$570$157,08611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 34 hematology & oncology providers in Idaho.

Other hematology & oncology in Rexburg

See the full list for Idaho →

Where these figures come from

Is this you, or does something look wrong? →